- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Buprenorphine safe for use in Hospitalized patients with Acute Hepatitis A: Study
![Buprenorphine safe for use in Hospitalized patients with Acute Hepatitis A: Study Buprenorphine safe for use in Hospitalized patients with Acute Hepatitis A: Study](https://medicaldialogues.in/h-upload/2021/08/25/750x450_159424-risks-and-benefits-of-suboxone-and-buprenorphine.webp)
Buprenorphine has a good safety profile when administered to hospitalized patients with Acute Hepatitis A suggests a study published in the Journal of Addiction Medicine.
Hepatitis A is an inflammation of the liver that can cause mild to severe illness. The hepatitis A virus (HAV) is transmitted by ingesting contaminated food and water or direct contact with an infectious person. Patients are admitted if they are showing any signs or symptoms suggestive of severe complications. Buprenorphine is FDA-approved for acute pain, chronic pain, and opioid dependence. It is not known whether buprenorphine/naloxone (bup/nx) can be safely initiated in hospitalized patients with acute hepatitis A infection.
A group of researchers from U.S.A assessed liver function and tolerability of buprenorphine/naloxone (bup/nx) induction in patients with acute Hepatitis A Virus (HAV).
The researchers conducted retrospective review of patients (N = 31) admitted to a tertiary care facility for acute Hepatitis A Virus (HAV) who were evaluated by an addiction medicine consultant.
The results of the study are as follows:
- No significant difference was seen in aspartate aminotransferase, alanine aminotransferase, total bilirubin, or INR trends in patients receiving buprenorphine/naloxone (bup/nx) during hospitalization versus those not receiving buprenorphine/naloxone (bup/nx).
- Nausea was the most commonly reported symptom in patients receiving buprenorphine/naloxone (bup/nx).
Thus, the researchers concluded that with careful monitoring and induction dose adjustment, buprenorphine/naloxone (bup/nx) could be administered to patients with acute HAV without hepatic encephalopathy. Similarly, patients on buprenorphine/naloxone (bup/nx) before hospitalization should not have this medication held in the setting of acute Hepatitis A Virus (HAV). And that this strategy may engage patients with acute HAV in treatment of OUD earlier and minimize disruptions in treatment.
Reference:
A study titled "Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A" by Oller D et al. published in the J Addict Med.
DOI: 10.1097/ADM.0000000000000730
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751